Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Amanda Calhoun, Je Ko & George T. Grossberg. (2017) Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease. Expert Opinion on Emerging Drugs 22:1, pages 101-105.
Read now
Read now
Diane Stephenson. (2015) Alzheimer’s disease: current and future therapy. Expert Review of Neurotherapeutics 15:1, pages 1-2.
Read now
Read now
Articles from other publishers (28)
Md. Ashrafur Rahman, Arif Anzum Shuvo, Md. Mehedi Hasan Apu, Monisha Rani Bhakta, Farzana Islam, Md. Atiqur Rahman, Md. Rabiul Islam & Hasan Mahmud Reza. (2023) Combination of epigallocatechin 3 gallate and curcumin improves d-galactose and normal-aging associated memory impairment in mice. Scientific Reports 13:1.
Crossref
Crossref
João Pedro Ferrari-Souza & Lucas Porcello Schilling. (2023) Rumo a uma nova era no diagnóstico e tratamento da doença de Alzheimer. PAJAR - Pan-American Journal of Aging Research 11:1, pages e44542.
Crossref
Crossref
Donald A. Berry, Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Lynn D. Kramer & Scott M. Berry. (2023) Lecanemab for Patients With Early Alzheimer Disease. JAMA Network Open 6:4, pages e237230.
Crossref
Crossref
George D. Wilson, C. Leland Rogers, Minesh P. Mehta, Brian Marples, Daniel B. Michael, James S. Welsh, Alvaro A. Martinez & James Fontanesi. (2023) The Rationale for Radiation Therapy in Alzheimer's Disease. Radiation Research 199:5.
Crossref
Crossref
Xingxin Pan, Jun Yun, Zeynep H. Coban Akdemir, Xiaoqian Jiang, Erxi Wu, Jason H. Huang, Nidhi Sahni & S. Stephen Yi. (2023) AI-DrugNet: A network-based deep learning model for drug repurposing and combination therapy in neurological disorders. Computational and Structural Biotechnology Journal 21, pages 1533-1542.
Crossref
Crossref
Martijn L.T.M. Müller & Diane T. Stephenson. 2023. Precision Medicine in Neurodegenerative Disorders, Part II. Precision Medicine in Neurodegenerative Disorders, Part II
347
360
.
Opeyemi B. Ogunsuyi, Folorunsho B. Omage, Omamuyovwi M. Ijomone, Ganiyu Oboh & João B. T. Rocha. (2022) Effect of chlorogenic acid plus donepezil on critical neurocortical enzyme activities, inflammatory markers, and synaptophysin immunoreactivity in scopolamine‐assaulted rats, supported by multiple ligand simultaneous docking. Journal of Food Biochemistry 46:11.
Crossref
Crossref
Enze Liu, Xue Wu, Lei Wang, Yang Huo, Huanmei Wu, Lang Li & Lijun Cheng. (2022) DSCN: Double-target selection guided by CRISPR screening and network. PLOS Computational Biology 18:8, pages e1009421.
Crossref
Crossref
Arash Salehipour, Motahareh Bagheri, Mohammadmahdi Sabahi, Mahsa Dolatshahi & Delphine Boche. (2022) Combination Therapy in Alzheimer’s Disease: Is It Time?. Journal of Alzheimer's Disease 87:4, pages 1433-1449.
Crossref
Crossref
Vesna Jelic & Bengt Winblad. 2021. Management of Patients with Dementia. Management of Patients with Dementia
73
104
.
Daniela J. Conrado, Sridhar Duvvuri, Hugo Geerts, Jackson Burton, Carla Biesdorf, Malidi Ahamadi, Sreeraj Macha, Gregory Hather, Juan Francisco Morales, Jagdeep Podichetty, Timothy Nicholas, Diane Stephenson, Mirjam Trame, Klaus Romero & Brian Corrigan. (2020) Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. Clinical Pharmacology & Therapeutics 107:4, pages 796-805.
Crossref
Crossref
Alberto J. Espay, Lorraine V. KaliaZiv Gan-OrCaroline H. Williams-GrayPhilippe L. Bedard, Steven M. RoweFrancesca MorganteAlfonso FasanoBenjamin StecherMarcelo A. KauffmanMatthew J. Farrer, Chris S. CoffeyMichael A. SchwarzschildTodd ShererRonald B. PostumaAntonio P. StrafellaAndrew B. SingletonRoger A. BarkerKarl KieburtzC. Warren OlanowAndres LozanoJeffrey H. KordowerJesse M. CedarbaumPatrik BrundinDavid G. Standaert & Anthony E. Lang. (2020) Disease modification and biomarker development in Parkinson disease. Neurology 94:11, pages 481-494.
Crossref
Crossref
Justin M. Long & David M. Holtzman. (2019) Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 179:2, pages 312-339.
Crossref
Crossref
Yuxuan Hu, Chia-hui Chen, Yang-yang Ding, Xiao Wen, Bingbo Wang, Lin Gao & Kai Tan. (2019) Optimal control nodes in disease-perturbed networks as targets for combination therapy. Nature Communications 10:1.
Crossref
Crossref
Diane T. Stephenson & Stephen P. Arnerić. 2019. Translational Medicine in CNS Drug Development. Translational Medicine in CNS Drug Development
277
296
.
Angie C.A. Chiang, Stephanie W. Fowler, Ricky R. Savjani, Susan G. Hilsenbeck, Clare E. Wallace, John R. Cirrito, Pritam Das & Joanna L. Jankowsky. (2018) Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. Journal of Experimental Medicine 215:5, pages 1349-1364.
Crossref
Crossref
Anthony E. Lang & Alberto J. Espay. (2018) Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Movement Disorders 33:5, pages 660-677.
Crossref
Crossref
Adithy Hassan, Meghan Robinson & Stephanie M. Willerth. (2018) Modeling the Effects of Yoga on the Progression of Alzheimer’s Disease in a Dish. Cells Tissues Organs 206:4-5, pages 263-271.
Crossref
Crossref
Michael Gold. (2017) Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?. Alzheimer's & Dementia: Translational Research & Clinical Interventions 3:3, pages 402-409.
Crossref
Crossref
Rui Hu, Pan Wei, Lu Jin, Teng Zheng, Wen-Yu Chen, Xiao-Ya Liu, Xiao-Dong Shi, Jing-Ru Hao, Nan Sun & Can Gao. (2017) Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model. Cell Death & Disease 8:3, pages e2717-e2717.
Crossref
Crossref
Randall J. Bateman, Tammie L. Benzinger, Scott Berry, David B. Clifford, Cynthia Duggan, Anne M. Fagan, Kathleen Fanning, Martin R. Farlow, Jason Hassenstab, Eric M. McDade, Susan Mills, Katrina Paumier, Melanie Quintana, Stephen P. Salloway, Anna Santacruz, Lon S. Schneider, Guoqiao Wang & Chengjie Xiong. (2016) The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimer's & Dementia 13:1, pages 8-19.
Crossref
Crossref
MR Trusheim, AA Shrier, Z Antonijevic, RA Beckman, RK Campbell, C Chen, KT Flaherty, J Loewy, D Lacombe, S Madhavan, HP Selker & LJ Esserman. (2016) PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. Clinical Pharmacology & Therapeutics 100:6, pages 713-729.
Crossref
Crossref
Todd E. Golde. (2016) Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. Journal of Neurochemistry 139, pages 224-236.
Crossref
Crossref
Alinda R. Fernandes & Divya M. Chari. (2016) Part I: Minicircle vector technology limits DNA size restrictions on ex vivo gene delivery using nanoparticle vectors: Overcoming a translational barrier in neural stem cell therapy. Journal of Controlled Release 238, pages 289-299.
Crossref
Crossref
Philip Scheltens, Kaj Blennow, Monique M B Breteler, Bart de Strooper, Giovanni B Frisoni, Stephen Salloway & Wiesje Maria Van der Flier. (2016) Alzheimer's disease. The Lancet 388:10043, pages 505-517.
Crossref
Crossref
James A. Hendrix, Randall J. Bateman, H. Robert Brashear, Cynthia Duggan, Maria C. Carrillo, Lisa J. Bain, Ronald DeMattos, Russell G. Katz, Susanne Ostrowitzki, Eric Siemers, Reisa Sperling & Ottavio V. Vitolo. (2016) Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. Alzheimer's & Dementia 12:5, pages 623-630.
Crossref
Crossref
Sandrine Andrieu, Nicola Coley, Simon Lovestone, Paul S Aisen & Bruno Vellas. (2015) Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. The Lancet Neurology 14:9, pages 926-944.
Crossref
Crossref
Nicola Coley, Adeline Gallini & Sandrine Andrieu. (2015) Prevention Studies in Alzheimer’s Disease: Progress Towards the Development of New Therapeutics. CNS Drugs 29:7, pages 519-528.
Crossref
Crossref